Data shows Illumina next-generation sequencing is the NIPT technology of choice
Published support of next generation sequencing (NGS)
Noninvasive prenatal testing (NIPT) provides accurate information about major chromosome abnormalities in a fetus as early as 10 weeks gestation using a single maternal blood draw.
- Next-generation sequencing (NGS) is the most-published method for performing NIPT1,2
- 99.7% of NIPT samples in published studies were run on Illumina NGS technology (Table 1)
1. The American College of Obstetricians and Gynecologists. Committee Opinion:Cell free DNA screening for fetal aneuploidy. www.acog.org/Resources-And-Publications/ Committee-Opinions/Committee-on-Genetics/Cell-free-DNA-Screening-for-Fetal-Aneuploidy. Published June 26, 2015. Accessed August 5, 2015.
2. Benn P, Borell A, Chiu R, et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis.Prenat Diagn.